	US 12,304,953 B2
	Anti-CD3 antibodies and uses thereof
Francois Gaudet, Princeton, NJ (US); Jill Giles-Komar, Downingtown, PA (US); Bradley Heidrich, Gilbertsville, PA (US); Chichi Huang, Malvern, PA (US); Colleen Kane, Flourtown, PA (US); Ronan Mcdaid, Eagleville, PA (US); and Jennifer Nemeth-Seay, Fort Washington, PA (US)
Assigned to Janssen Biotech, Inc., Horsham, PA (US)
Filed by Janssen Biotech, Inc., Horsham, PA (US)
Filed on Mar. 8, 2023, as Appl. No. 18/180,225.
Application 18/180,225 is a continuation of application No. 16/418,082, filed on May 21, 2019, granted, now 11,603,405.
Claims priority of provisional application 62/676,081, filed on May 24, 2018.
Prior Publication US 2023/0322924 A1, Oct. 12, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2809 (2013.01) [A61K 39/39541 (2013.01); A61P 35/00 (2018.01); C07K 16/28 (2013.01); C07K 16/2803 (2013.01); C07K 16/3069 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/55 (2013.01); C07K 2317/92 (2013.01)]

19 Claims

1. A recombinant multispecific antibody comprising a first domain, wherein the first domain specifically binds CD3, a second binding domain wherein the second binding domain specifically binds a second antigen, and a third binding domain wherein the third binding domain specifically binds a third antigen, wherein the first binding domain comprises a heavy chain variable region (VH) and a light chain variable region (VL) of SEQ ID NOs: 652 and 661, respectively,

wherein the multispecific antibody is an IgG1 isotype and comprises substitutions comprising (i) L234A and L235A, (ii) T366S, L368A, and Y407V substitutions, and (iii) T366W, and

wherein residue numbering is according to the EU Index.